Revolution Medicines, Inc. RVMD
Set alert
At close · Nov 2
After hours · Nov 2, 4:33 PM ET
- YTD
- +136.25%
- 1 year
- +219.80%
- Open
- 190.71
- Prev close
- 191.31
- Mkt cap
- 40.33B
- Vol
- 1.37M
- Avg vol
- 1.93M
- EPS
- -8.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 187.12
- High
- 192.98
- Forward P/E
- -32.65
- Beta
- 1.43
- Short ratio
- 5.55
- Inst. own
- 103.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 199.22
- 200-d avg
- 156.04
- 1y target
- 258.84
5D chart
Signals (144)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 3:55 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:50 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:50 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:45 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 3:40 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:35 PM | 9 hours ago |
| SMA: Bearish | Nov 2, 3:30 PM | 9 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 2:55 PM | 10 hours ago |
| MACD: Buy Signal | Nov 2, 2:55 PM | 10 hours ago |
| MACD: Sell Signal | Nov 2, 2:30 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 2:25 PM | 10 hours ago |
| SMA: Bearish | Nov 2, 2:15 PM | 10 hours ago |
| SMA: Bullish | Nov 2, 2:10 PM | 11 hours ago |
| MACD: Buy Signal | Nov 2, 2:05 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 2:00 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 1:50 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 1:45 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 1:25 PM | 11 hours ago |
| SMA: Bullish | Nov 2, 1:20 PM | 11 hours ago |
Newest 20 of 144.
News
1 day ago benzinga.com
Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week
Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
4 days ago fool.com
Could Revolution Medicines Be a Millionaire-Maker Stock?
Revolution Medicines' stock has soared over 9x in three years. This success has been driven by excitement about the company's cancer drug, Rasonque.
5 days ago benzinga.com
Jim Cramer: This Tech Stock ‘Sells At A Low Multiple’
Jim Cramer favors Penguin Solutions for its low valuation after strong earnings and says investors should let Revolution Medicines run.
5 days ago defenseworld.net
Revolution Medicines, Inc. $RVMD Holdings Cut by Citizens Financial Group Inc. RI
Citizens Financial Group Inc. RI cut its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 92.4% in the third quarter, according to the company in its most recent filing with the…
6 days ago fool.com
Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?
Stanley Druckenmiller's Duquesne Family Office increased its stake in Revolution Medicines during the second quarter. The biotech earned approval for an innovative medicine for pancreatic cancer in…
6 days ago globenewswire.com
Revolution Medicines to Participate in November 2026 Investor Conferences
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering…
1 week ago benzinga.com
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
1 week ago benzinga.com
Here’s How Much You Would Have Made Owning Revolution Medicines Stock In The Last 5 Years
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.96% on an annualized basis producing an average annual return of 46.71%. Currently, Revolution Medicines has…
-
1 week ago benzinga.com
Revolution Medicines Presents Exploratory Subgroup Analyses From Phase 3 RASolute 302 Trial, As Late-Breaking Abstract At ESMO Congress 2026
Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory subgroup analyses showed RASONQUE consistently provided an overall survival…
1 week ago globenewswire.com
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
REDWOOD CITY, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering…
-
1 week ago benzinga.com
Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
1 week ago globenewswire.com
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering…
-
1 week ago benzinga.com
TD Cowen Reiterates Buy on Revolution Medicines, Announces $250 Price Target
TD Cowen analyst Tyler Van Buren reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $250 price target.
1 week ago benzinga.com
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer.
1 week ago benzinga.com
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Revolution Medicines doses first patients in its global Phase 3 trial testing zoldonrasib for metastatic non-small cell lung cancer.
1 week ago globenewswire.com
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering…
-
2 weeks ago benzinga.com
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $241
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $241.
2 weeks ago defenseworld.net
7,403 Shares in Revolution Medicines, Inc. $RVMD Purchased by SteelPeak Wealth LLC
SteelPeak Wealth LLC acquired a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
2 weeks ago defenseworld.net
3,373 Shares of Revolution Medicines, Inc. $RVMD Bought by First Citizens Bank & Trust Co.
First Citizens Bank and Trust Co. purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) during the third quarter, according to the company in its most recent 13F filing with…
2 weeks ago benzinga.com
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Revolution Medicines Inc. (NASDAQ:RVMD) has significant growth opportunities beyond pancreatic cancer, according to William Blair, which initiated coverage of the biotechnology company with an…
2 weeks ago benzinga.com
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.
-
2 weeks ago benzinga.com
William Blair Initiates Coverage On Revolution Medicines with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Outperform rating.
2 weeks ago defenseworld.net
Revolution Medicines, Inc. $RVMD Stock Acquired by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 987.9% in the undefined quarter, according to the company in its most recent filing with…
2 weeks ago globenewswire.com
Revolution Medicines' RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically…
-
2 weeks ago benzinga.com
Needham Reiterates Buy on Revolution Medicines, Maintains $275 Price Target
Needham analyst Ami Fadia reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $275 price target.
2 weeks ago benzinga.com
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 36.7% on an annualized basis producing an average annual return of 48.0%. Currently, Revolution Medicines has a…
-
2 weeks ago benzinga.com
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.
3 weeks ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
3 weeks ago benzinga.com
Stock Market Today: S&P 500 Slips as Oil Spikes 5%, 10-Year Yields Near 5.35%
Stocks slip as Gulf tanker attacks lift Brent above $105 and the 10-year yield nears 5.35%; small caps lag while energy and Chipotle rally.
-
3 weeks ago benzinga.com
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $259
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $251 to $259.
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $239 to $240.
4 weeks ago 247wallst.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Align Technology, AutoNation, Estee Lauder, Harley-Davidson, HubSpot, Microsoft, Mosaic, Ryder System, Wells Fargo & Company, and More
Wall Street kicked off the first full week of Q4 2026 with a flurry of bold analyst moves, including a sweeping Microsoft upgrade and a brutal Align Technology target slash. Find out which names got…
-
4 weeks ago benzinga.com
Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers,…
4 weeks ago globenewswire.com
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering…
-
1 month ago benzinga.com
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.
1 month ago defenseworld.net
Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Elizabeth Anderson sold 10,143 shares of the firm's stock in a transaction that occurred on Tuesday, September 22nd. The stock was…
1 month ago fool.com
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.
-
1 month ago benzinga.com
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an annualized basis producing an average annual return of 45.32%. Currently, Revolution Medicines has…
-
1 month ago benzinga.com
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.
1 month ago defenseworld.net
Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Alan Sandler sold 341 shares of Revolution Medicines stock in a transaction dated Wednesday, September 16th. The stock was sold at…
1 month ago defenseworld.net
Jack Anders Sells 4,053 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 4,053 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at…
1 month ago fool.com
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline…
-
1 month ago benzinga.com
Morgan Stanley Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $255
Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Overweight rating and announces Price Target of $255.
-
1 month ago benzinga.com
Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230
Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.
1 month ago benzinga.com
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an annualized basis producing an average annual return of 46.85%. Currently, Revolution Medicines has…
-
2 months ago benzinga.com
Reported Earlier, Revolution Medicines Lung Cancer Drug Shows 42% Response Rate In Early Trial
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers,…
2 months ago benzinga.com
Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.
2 months ago benzinga.com
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
2 months ago benzinga.com
Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO…